Thorsen S, Philips M
Biochim Biophys Acta. 1984 Nov 6;802(1):111-8. doi: 10.1016/0304-4165(84)90040-0.
Plasminogen activator-inhibitor complexes were analyzed by SDS-polyacrylamide gel electrophoresis and enzymography. The complexes appeared as fibrinolytically active bands in the fibrin-indicator gel. A high-molecular-weight t-PA form comigrating with a t-PA-inhibitor complex (Mr 95 000-135 000) from cultured human endothelial cells was purified from plasma by immunoadsorption on anti-t-PA-Sepharose followed by gel filtration on Sephadex G-150. The high-molecular-weight t-PA form was fibrinolytically inactive when assayed by the fibrin-plate method. It was converted to a form with the same electrophoretic mobility as t-PA (Mr 72 000) when treated with 1.5 M NH4OH/39 mM SDS. These observations suggested that the plasma high-molecular-weight t-PA form was an enzyme-inhibitor complex. The complex did not show immunological cross-reactivity with a number of known plasma serine proteinase inhibitors. Both t-PA and u-PA rapidly formed complexes with an inhibitor which was present in plasma in pmolar concentrations. p-Aminobenzamidine blocked the reaction, indicating that the active center of the activator was indeed implicated in complex formation. The complex between the plasma inhibitor and t-PA and the high-molecular-weight t-PA had the same electrophoretic mobilities. The rapid plasminogen activator inhibitor in plasma showed remarkable similarity to a plasminogen activator inhibitor from cultured human endothelial cells. In addition to the high-molecular-weight t-PA form described above, three other t-PA forms were isolated from plasma. Our results indicated that they represented free t-PA and t-PA in complex with respectively C1-esterase inhibitor and alpha 2-antiplasmin.
通过十二烷基硫酸钠-聚丙烯酰胺凝胶电泳和酶谱法分析纤溶酶原激活物-抑制剂复合物。这些复合物在纤维蛋白指示凝胶中表现为具有纤溶活性的条带。通过抗组织型纤溶酶原激活物(t-PA)-琼脂糖免疫吸附,随后在葡聚糖凝胶G-150上进行凝胶过滤,从血浆中纯化出一种与来自培养的人内皮细胞的t-PA-抑制剂复合物(分子量95000 - 135000)共迁移的高分子量t-PA形式。用纤维蛋白平板法检测时,该高分子量t-PA形式无纤溶活性。用1.5 M氢氧化铵/39 mM十二烷基硫酸钠处理后,它转变为与t-PA(分子量72000)具有相同电泳迁移率的形式。这些观察结果表明血浆中的高分子量t-PA形式是一种酶-抑制剂复合物。该复合物与许多已知的血浆丝氨酸蛋白酶抑制剂没有免疫交叉反应。t-PA和尿激酶型纤溶酶原激活物(u-PA)都能与血浆中以皮摩尔浓度存在的一种抑制剂迅速形成复合物。对氨基苯甲脒阻断了该反应,表明激活物的活性中心确实参与了复合物的形成。血浆抑制剂与t-PA之间的复合物以及高分子量t-PA具有相同的电泳迁移率。血浆中的快速纤溶酶原激活物抑制剂与来自培养的人内皮细胞的纤溶酶原激活物抑制剂表现出显著的相似性。除了上述高分子量t-PA形式外,还从血浆中分离出另外三种t-PA形式。我们的结果表明,它们分别代表游离t-PA以及与C1酯酶抑制剂和α2抗纤溶酶形成复合物的t-PA。